Business Context and Reporting Period
This Form 6-K is filed by Trinity Biotech PLC, a foreign private issuer headquartered in Bray, Co. Wicklow, Ireland. The report covers the month of June 2026 and is signed by Paul Murphy, Interim Chief Financial Officer, on June 5, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or total debt. The document focuses exclusively on a specific amendment to the company's credit agreement with its lender, Perceptive Credit Holdings III, LP.
Material Changes
- Interest Capitalization: The company and Perceptive agreed that interest payable under the credit agreement for May 2026 will be capitalized and added to the principal balance outstanding.
- Covenant Waiver: Perceptive granted a limited waiver regarding Section 8.15 of the credit agreement for June 2026.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of general risks. The primary contingency noted is the modification of debt terms, specifically the deferral of interest payments and the waiver of a specific covenant section.
Investor Verification Checklist
- Verify the updated principal balance of the credit agreement following the capitalization of May 2026 interest.
- Review the specific terms of the limited waiver for Section 8.15 of the credit agreement to understand any remaining compliance obligations.
- Confirm the status of the Interim Chief Financial Officer role and any potential impact on financial reporting continuity.